Issues
-
Cover Image
Cover Image
The components and transcriptional targets of the canonical Wnt signaling pathway are frequently altered and serve as major oncogenic drivers in hepatocellular carcinoma. Zebrafish larvae emerged as unique models for studying early stage tumorigenesis due to their small size and optical transparency. In a triple transgenic zebrafish larva, fabp10a:TetOn; TRE:GAL4-VP16 expresses the inducible transactivator TetOn via the hepatocyte-specific promoter; TRE:ABC-P2A-tcf7l2 expresses human CTNNB1 carrying four typical mutations and zebrafish tcf7l2 ectopically in the zebrafish liver; TCFSiam:mCherry, a transcriptional reporter for canonical Wnt activity, labels the Wnt-responsive cells. Meanwhile, TRE:eGFP-KrasV12 conditionally activates Ras signaling. Together, the zebrafish larva displays significant hepatomegaly and severe hyperplasia within three days in doxycycline induction, with double oncogenic pathway activated. For details, see article by Yao and colleagues on page 5548. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Insights
Reviews
Cancer Research Highlights
Perspective
Priority Reports
Genome and Epigenome
Molecular Cell Biology
Replication Protein A Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells
Tumor Biology and Immunology
Macrophage-Derived Neuropilin-2 Exhibits Novel Tumor-Promoting Functions
Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss
Pharmacologically targeting the stromal p38MAPK-MK2 pathway limits metastatic breast cancer growth, preserves bone quality, and extends survival.
Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer–Mediated Cytotoxicity
Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice
Translational Science
Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547
Convergence and Technologies
Correction
Retraction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.